Signal 2 initiates T cell proliferation, the biological process during which T cells multiply to expand the arsenal of immune cells that recognize the antigen and kill cancer cells. Next, the immune ...

After CAR T-cell therapy led to complete remission with incomplete hematologic recovery, patients received haploidentical HSCT without pharmacologic myeloablation or GVHD prophylaxis drugs.

A laboratory testing partner can help developers and sponsors of CAR T-cell therapies cope with regulatory shifts and unique testing challenges.

KLF7 is known to promote T cell proliferation. When analyzing samples from LBCL patients treated with CAR-T therapy, they found that the CAR-T cells with higher levels of KLF7 were associated with ...

Synthetic suppressor T cells successfully curbed CAR T cell proliferation in the dual-antigen tumor, demonstrating their ability to regulate immune responses in vivo.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and ...

The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind ...

T-cells are a type of immune cell, and lymphoproliferative disorders are conditions that cause the body to make uncontrolled amounts of white blood cells called lymphocytes.

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in previous studies. This is shown in a new compilation of Swedish treatment ...